Benzinga | Aug 10, 2021 06:15AM EDT

Fennec Pharmaceuticals Q2 EPS $(0.15) Beats $(0.19) Estimate

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 28.57 percent increase over losses of $(0.21) per share from the same period last year.